These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3506266)

  • 1. [Multiple myeloma. Clinical experience of 15 years in the 10th region].
    Cristoffanini AP; Vidal MA; Cea X; Zapata C
    Rev Med Chil; 1987 Nov; 115(11):1061-5. PubMed ID: 3506266
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
    Gruber A; Osby E
    Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of the prognosis and response to therapy in multiple myeloma].
    Venturino M; Geniram A; Guarino P; Scio P; Marini U
    Recenti Prog Med; 1984 May; 75(5):451-61. PubMed ID: 6484288
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value of protocols of alternating chemotherapy versus melphalan-prednisone during the induction phase of stage III myelomas. Critical review].
    Paule B; Medicis P; Clerc D; Bennet P; Bisson M; Massias P
    Rev Rhum Mal Osteoartic; 1987 Dec; 54(12):827-32. PubMed ID: 3324290
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
    Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
    Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year survival in multiple myeloma: report of two cases and review of the literature.
    Rosner F; Grünwald HW; Kalman AC
    N Y State J Med; 1992 Jul; 92(7):316-8. PubMed ID: 1518591
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple myeloma in a child.
    Prematilleke MN
    Ceylon Med J; 1987 Sep; 32(3):143-5. PubMed ID: 3447753
    [No Abstract]   [Full Text] [Related]  

  • 10. [Multiple myeloma: therapeutic response to 2 modalities of chemotherapy].
    Lira P; Walker B; Grebe G
    Rev Med Chil; 1986 May; 114(5):436-40. PubMed ID: 3589221
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 12. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of elderly patients with multiple myeloma.
    Facon T
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of chemotherapy in multiple myeloma.
    Djulbegovic B; Blumenreich M; Hadley T; Joseph G
    J Clin Oncol; 1992 Aug; 10(8):1366-7. PubMed ID: 1386103
    [No Abstract]   [Full Text] [Related]  

  • 16. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
    Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
    Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    Hernández JM; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler JA; Gardella S; Carbonell F; Mateo G; San Miguel JF
    Br J Haematol; 2004 Oct; 127(2):159-64. PubMed ID: 15461621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 19. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications for chemotherapy in multiple myeloma].
    Heyll A; Aul C
    Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.